CD8A and neoplasm: In a trial, low-dose multitarget TKIs, through causing durable tumor vascular normalization and intratumoral CD4+ T, CD8+ T, and NK cell infiltrations, independent of interferon γ, improved the results of anti-PD-1 therapy with fewer side effects.